Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Results of the Beat AML umbrella study for previously untreated acute myeloid leukaemia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.12.18
Views: 737

Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA

Dr Amy Burd speaks to ecancer at ASH 2018 about results from Beat AML study for or previously untreated acute myeloid leukaemia (AML), the most lethal form of adult leukaemia.

She reports that rapid genetic screening shows feasibility of precision medicine for acute myeloid leukaemia.

Dr Burd concludes that, with so many targeted drugs becoming available, a precision medicine approach is going to become even more important in clinical practice.

Watch Dr Burd's press conference here.

Read the article here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

CML Life Banner

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation